EA200100153A1 - JOINT APPOINTMENT OF ASAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC DEFECTS - Google Patents
JOINT APPOINTMENT OF ASAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC DEFECTSInfo
- Publication number
- EA200100153A1 EA200100153A1 EA200100153A EA200100153A EA200100153A1 EA 200100153 A1 EA200100153 A1 EA 200100153A1 EA 200100153 A EA200100153 A EA 200100153A EA 200100153 A EA200100153 A EA 200100153A EA 200100153 A1 EA200100153 A1 EA 200100153A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- asat
- atherosclerotic
- defects
- treatment
- mmp inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Furan Compounds (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Предмет данного изобретения составляет совместное назначение веществ, ингибирующих АСАТ и ММР, для понижения компонентов атеросклеротического поражения, связанных с макрофагами и с клетками гладких мышц, которое приводит к ослаблению экспансии существующих поражений и развития новых поражений, предупреждает отрыв бляшек и способствует регрессии поражений у млекопитающих.Отчет о международном поиске был опубликован 2000.05.18.The object of this invention is the joint appointment of ASAT and MMP inhibiting substances to reduce atherosclerotic lesion components associated with macrophages and smooth muscle cells, which leads to a weakening of the expansion of existing lesions and the development of new lesions, prevents plaque detachment and promotes regression of lesions in mammals. The international search report was published on 2000.05.18.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9363998P | 1998-07-21 | 1998-07-21 | |
| PCT/US1999/013948 WO2000004892A2 (en) | 1998-07-21 | 1999-06-18 | Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200100153A1 true EA200100153A1 (en) | 2001-08-27 |
Family
ID=22239992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200100153A EA200100153A1 (en) | 1998-07-21 | 1999-06-18 | JOINT APPOINTMENT OF ASAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC DEFECTS |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1098662A2 (en) |
| JP (1) | JP2002521328A (en) |
| KR (1) | KR20010083134A (en) |
| CN (1) | CN1310629A (en) |
| AP (1) | AP2001002035A0 (en) |
| AU (1) | AU4701799A (en) |
| BG (1) | BG105162A (en) |
| BR (1) | BR9912296A (en) |
| CA (1) | CA2335062A1 (en) |
| CZ (1) | CZ2001126A3 (en) |
| EA (1) | EA200100153A1 (en) |
| EE (1) | EE200100046A (en) |
| HR (1) | HRP20010055A2 (en) |
| HU (1) | HUP0102880A3 (en) |
| ID (1) | ID30030A (en) |
| IL (1) | IL140982A0 (en) |
| IS (1) | IS5809A (en) |
| NO (1) | NO20010291L (en) |
| OA (1) | OA11584A (en) |
| PL (1) | PL346011A1 (en) |
| SK (1) | SK502001A3 (en) |
| TR (1) | TR200100205T2 (en) |
| WO (1) | WO2000004892A2 (en) |
| YU (1) | YU3501A (en) |
| ZA (1) | ZA200100294B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2382676A1 (en) * | 1999-11-05 | 2001-05-17 | Warner-Lambert Company | Prevention of plaque rupture by acat inhibitors |
| DOP2000000107A (en) | 1999-12-01 | 2002-09-16 | Agouron Pharmaceutical Inc | COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND LENGTH OF NEURONS |
| AU2268401A (en) * | 1999-12-17 | 2001-06-25 | Versicor Inc | Novel succinate compounds, compositions and methods of use and preparation |
| PL362244A1 (en) * | 2000-09-01 | 2004-10-18 | Sankyo Company, Limited | Medicinal compositions |
| GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| CA2479906C (en) * | 2002-04-03 | 2011-02-08 | Topotarget Uk Limited | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
| CA2492035A1 (en) * | 2002-07-11 | 2004-01-15 | Vicuron Pharmaceuticals, Inc. | N-hydroxyamide derivatives possessing antibacterial activity |
| WO2011092284A1 (en) * | 2010-01-29 | 2011-08-04 | Euroscreen S.A. | Novel amino acid derivatives and their use as gpr43 receptor modulators |
| CN104211695B (en) * | 2013-06-04 | 2017-04-12 | 中国医学科学院医药生物技术研究所 | Use of group of carbamyl phenylsulfonyl compounds |
| EP3244883A1 (en) * | 2015-01-15 | 2017-11-22 | Biocant - Associação De Transferência De Tecnologia | Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing |
| CN106831697B (en) * | 2017-03-15 | 2019-11-05 | 深圳市康道生物有限公司 | The effective extract component of river hazel and its application in prevention and treatment atherosclerosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5366987A (en) * | 1991-08-22 | 1994-11-22 | Warner-Lambert Company | Isoxazolyl-substituted alkyl amide ACAT inhibitors |
| US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
| EE9800037A (en) * | 1995-08-04 | 1998-08-17 | Warner-Lambert Company | Use of sulphamic acid derivatives, acylsulphonamides or sulphonylcarbamates in the manufacture of a medicament for reducing lipoprotein levels |
| DK0901466T3 (en) * | 1996-05-17 | 2002-02-18 | Warner Lambert Co | Biphenylsulfonamide-matriksmetalloproteinase inhibitors |
| BR9711988A (en) * | 1996-09-04 | 1999-08-24 | Warner Lambert Co | Matrix metalloproteinase inhibitors and their therapeutic uses |
-
1999
- 1999-06-18 CN CN99808958A patent/CN1310629A/en active Pending
- 1999-06-18 CZ CZ2001126A patent/CZ2001126A3/en unknown
- 1999-06-18 SK SK50-2001A patent/SK502001A3/en unknown
- 1999-06-18 EA EA200100153A patent/EA200100153A1/en unknown
- 1999-06-18 WO PCT/US1999/013948 patent/WO2000004892A2/en not_active Application Discontinuation
- 1999-06-18 AU AU47017/99A patent/AU4701799A/en not_active Abandoned
- 1999-06-18 IL IL14098299A patent/IL140982A0/en unknown
- 1999-06-18 EE EEP200100046A patent/EE200100046A/en unknown
- 1999-06-18 PL PL99346011A patent/PL346011A1/en unknown
- 1999-06-18 ID IDW20010333A patent/ID30030A/en unknown
- 1999-06-18 OA OA1200100022A patent/OA11584A/en unknown
- 1999-06-18 EP EP99930483A patent/EP1098662A2/en not_active Withdrawn
- 1999-06-18 TR TR2001/00205T patent/TR200100205T2/en unknown
- 1999-06-18 KR KR1020017000930A patent/KR20010083134A/en not_active Application Discontinuation
- 1999-06-18 AP APAP/P/2001/002035A patent/AP2001002035A0/en unknown
- 1999-06-18 JP JP2000560885A patent/JP2002521328A/en active Pending
- 1999-06-18 CA CA002335062A patent/CA2335062A1/en not_active Abandoned
- 1999-06-18 BR BR9912296-0A patent/BR9912296A/en not_active IP Right Cessation
- 1999-06-18 YU YU3501A patent/YU3501A/en unknown
- 1999-06-18 HU HU0102880A patent/HUP0102880A3/en unknown
-
2001
- 2001-01-10 ZA ZA200100294A patent/ZA200100294B/en unknown
- 2001-01-12 IS IS5809A patent/IS5809A/en unknown
- 2001-01-17 BG BG105162A patent/BG105162A/en unknown
- 2001-01-18 NO NO20010291A patent/NO20010291L/en not_active Application Discontinuation
- 2001-01-19 HR HR20010055A patent/HRP20010055A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ID30030A (en) | 2001-11-01 |
| TR200100205T2 (en) | 2001-05-21 |
| HUP0102880A2 (en) | 2002-06-29 |
| HUP0102880A3 (en) | 2002-11-28 |
| CA2335062A1 (en) | 2000-02-03 |
| IL140982A0 (en) | 2002-02-10 |
| JP2002521328A (en) | 2002-07-16 |
| NO20010291D0 (en) | 2001-01-18 |
| IS5809A (en) | 2001-01-12 |
| PL346011A1 (en) | 2002-01-14 |
| KR20010083134A (en) | 2001-08-31 |
| NO20010291L (en) | 2001-01-18 |
| EE200100046A (en) | 2002-06-17 |
| AU4701799A (en) | 2000-02-14 |
| HRP20010055A2 (en) | 2002-04-30 |
| WO2000004892A3 (en) | 2000-05-18 |
| BG105162A (en) | 2001-12-29 |
| WO2000004892A2 (en) | 2000-02-03 |
| AP2001002035A0 (en) | 2001-03-31 |
| CN1310629A (en) | 2001-08-29 |
| CZ2001126A3 (en) | 2002-01-16 |
| EP1098662A2 (en) | 2001-05-16 |
| YU3501A (en) | 2005-06-10 |
| ZA200100294B (en) | 2002-01-10 |
| OA11584A (en) | 2004-07-20 |
| SK502001A3 (en) | 2002-06-04 |
| BR9912296A (en) | 2001-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200100153A1 (en) | JOINT APPOINTMENT OF ASAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC DEFECTS | |
| DE602004025030D1 (en) | FUSSGELARTARTHROPLASTIE SYSTEM | |
| DE1073432T1 (en) | USE OF GLYCINE RECEPTORAGONISTS AND GLYCINE INHIBITOR INHIBITORS FOR THE TREATMENT OF NEUROPSYCHIATRIC COMPLAINTS | |
| ITBO990430A0 (en) | MEANS OF FEMORAL FIXATION OF THE SEMITENDINOSIS AND GRACIL TENDONS AND FOR THE RECONSTRUCTION OF THE ANTERIOR CRUCATE LIGAMENT. | |
| EA199900384A1 (en) | DEVICE FOR CLEANING INTERSTENTAL INTERMEDIATE AND METHOD OF ITS MANUFACTURE | |
| BR9813228A (en) | Formulation of 2-methyl-thieno-benzodiazepine | |
| NO975747L (en) | Peptidyl heterocycles for use in the treatment of thrombin-related deficiencies | |
| ATE241977T1 (en) | USE OF ANTI-MICROTUBULAR AGENTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | |
| EA200200208A1 (en) | SYNERGY COMPOSITION | |
| ES2178157T3 (en) | TREATMENT OF ARRITMIAS THROUGH THE INHIBITION OF A MULTIFUNCTIONAL KINASE PROTEIN DEPENDENT ON CALCIUM / CALMODULIN. | |
| AU5624699A (en) | Use of 5ht-6 antagonists | |
| NO20000268L (en) | Use of Lactobacillus for reduction of fibrinogen level in blood | |
| DE69725052D1 (en) | Connecting pin for multi-part orthopedic implant | |
| EA200000536A1 (en) | APPLICATION OF THE COMBINATION OF THE CONVERTER ENZYME INHIBITOR AND DIURETICS FOR THE TREATMENT OF MICROCIRCULATION DISORDERS | |
| ID27544A (en) | MUSCARINAT AGONISTS AND ANTAGONISTS | |
| DE69917663D1 (en) | 2-Methyl-THIENO BENZODIAZEPINE FORMULATION | |
| EE200000146A (en) | Combination of monoamine oxidase inhibitor with h5-HT1B antagonist or partial agonist | |
| FR2607004B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DILTIAZEM AND AN ANGIOTENSIN CONVERSION ENZYME INHIBITOR | |
| ES2168816T3 (en) | INJECTION CEMENT CONTAINING CORROSION INHIBITORS. | |
| DE29618426U1 (en) | Structured contact surface for medical purposes | |
| ATE261434T1 (en) | TRIPTOLIDE DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| NO995914L (en) | Procedure for detecting the risk of thrombosis | |
| BR9714376A (en) | Somatostatin antagonists | |
| BR9704653A (en) | Process for increasing the life span of dental components | |
| DK0904070T3 (en) | Use of the buckminster fuller for the treatment of neurotoxic lesions |